3 Stocks Cathie Wood Is Buying That Should Be on Your List Too

Motley Fool2021-06-24

Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

597

Report

Comment（173）

MillieZ
·2021-07-01
U is in my list，but still waiting the price up
Reply
Like
Report
兔气扬眉
·2021-06-26
[Smile]
Reply
Like
Report
StarGate
·2021-06-25
Noted
Reply
Like
Report
MajorJackpot
·2021-06-25
Ok
Reply
Like
Report
LimHianYew
·2021-06-25
Will try to follow
Reply
1
Report
Gab_Boey
·2021-06-25
Nice!
Reply
2
Report
HVLeo
·2021-06-25
It’s never too late to invest.
Reply
5
Report
Fold Replies
- 小霖妹子:
  True But also have to base on each individual’s risk capabilitY i guEss
  2021-06-26
  Reply
  Report
Sagi08
·2021-06-25
Like and comment
Reply
2
Report
Fold Replies
- Kelvinyoon26:
  ?
  2021-06-25
  Reply
  Report
- Junren92:
  good
  2021-06-25
  Reply
  Report
- IZLIN:
  [Thinking]
  2021-06-25
  Reply
  Report
HenryGoei
·2021-06-25
I will go buy
Reply
1
Report
SteveGoh
·2021-06-25
Like and comment please
Reply
4
Report
Fold Replies
- SerenityMie:
  done
  2021-06-25
  Reply
  Report
- Thengz:
  Ok
  2021-06-25
  Reply
  Report
Newcomer007
·2021-06-25
Nice.
Reply
3
Report
Kevin92
·2021-06-25
lke and comment
Reply
1
Report
Fold Replies
- SteveGoh:
  like and back please
  2021-06-25
  Reply
  Report
kukumolu
·2021-06-25
Nice
Reply
2
Report
Fold Replies
- Kevin92:
  lke and comment
  2021-06-25
  Reply
  Report
- TradeInWind:
  ?
  2021-06-25
  Reply
  Report
Legend_传奇
·2021-06-25
??
Reply
1
Report
Wallstrtbets
·2021-06-25
Arked.
Reply
3
Report
wooooow
·2021-06-25
O
Reply
Like
Report
happymoney
·2021-06-25
Cathie buy, i buy
Reply
Like
Report
Nebhol
·2021-06-25
Like comment
Reply
4
Report
Blim
·2021-06-25
Nice
Reply
3
Report
MaxWin
·2021-06-25
@kellyWin @chokim @NgeChanWinhhuat
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2145704596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-24 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2145704596","market":"us","top_or_hot":-1,"title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","media":"Motley Fool","content":"<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","article_id":"2145704596","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","pubTimestamp":1624533000,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These beaten-down stocks could still be big winners over the long run.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药","ETSY":"Etsy, Inc.","U":"Unity Software Inc."},"translate_title":"凯茜·伍德正在购买的3只股票也应该在你的名单上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARKIU":0.9,"ETSY":0.9,"U":0.9,"VRTX":0.9},"content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":158201856,"gmtCreate":1625149716975,"gmtModify":1703737233058,"author":{"id":"3557961101904469","authorId":"3557961101904469","authorIdStr":"3557961101904469","name":"MillieZ","avatar":"https://static.tigerbbs.com/c956f9d350d68b1ae5fcb45efecbc52f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3557961101904469"},"htmlText":"U is in my list，but still waiting the price up","listText":"U is in my list，but still waiting the price up","text":"U is in my list，but still waiting the price up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158201856","repostId":2145704596,"repostType":2,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":125153129,"gmtCreate":1624665419461,"gmtModify":1703842986085,"author":{"id":"3568026014768326","authorId":"3568026014768326","authorIdStr":"3568026014768326","name":"兔气扬眉","avatar":"https://community-static.tradeup.com/news/58fe9e54c89b636f385d436c63c3e4f2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3568026014768326"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/125153129","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126444435,"gmtCreate":1624582990227,"gmtModify":1703840875181,"author":{"id":"3586990023332519","authorId":"3586990023332519","authorIdStr":"3586990023332519","name":"StarGate","avatar":"https://static.tigerbbs.com/9db084b2eae373a6cc56043329defb07","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586990023332519"},"htmlText":"Noted&nbsp;","listText":"Noted&nbsp;","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126444435","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126554403,"gmtCreate":1624579727502,"gmtModify":1703840720289,"author":{"id":"3571016679890290","authorId":"3571016679890290","authorIdStr":"3571016679890290","name":"MajorJackpot","avatar":"https://static.tigerbbs.com/8e3167dc36bc3dc440bfc86312381fbb","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571016679890290"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126554403","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126584580,"gmtCreate":1624578912740,"gmtModify":1703840677656,"author":{"id":"3576363559636103","authorId":"3576363559636103","authorIdStr":"3576363559636103","name":"LimHianYew","avatar":"https://static.tigerbbs.com/6d37a520eb4e35950b060938ddb5e317","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3576363559636103"},"htmlText":"Will try to follow&nbsp;","listText":"Will try to follow&nbsp;","text":"Will try to follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126584580","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126534524,"gmtCreate":1624578365968,"gmtModify":1703840649707,"author":{"id":"3579833810423165","authorId":"3579833810423165","authorIdStr":"3579833810423165","name":"Gab_Boey","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579833810423165"},"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126534524","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126509858,"gmtCreate":1624577536874,"gmtModify":1703840609720,"author":{"id":"3571545243163999","authorId":"3571545243163999","authorIdStr":"3571545243163999","name":"HVLeo","avatar":"https://static.tigerbbs.com/274741917269dc1bc77e5d1aa08f9411","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3571545243163999"},"htmlText":"It’s never too late to invest.&nbsp;","listText":"It’s never too late to invest.&nbsp;","text":"It’s never too late to invest.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/126509858","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5026193,"gmtCreate":1624683169014,"gmtModify":1663230062958,"authorId":3579326417741698,"author":{"id":3579326417741698,"authorId":3579326417741698,"name":"小霖妹子","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.15","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126509858,"type":1,"supId":0,"prevId":0,"content":"True But also have to base on each individual’s risk capabilitY i guEss ","text":"True But also have to base on each individual’s risk capabilitY i guEss ","html":"True But also have to base on each individual’s risk capabilitY i guEss "}],"langContent":"EN"},{"id":126271626,"gmtCreate":1624577311865,"gmtModify":1703840598830,"author":{"id":"3582026494482473","authorId":"3582026494482473","authorIdStr":"3582026494482473","name":"Sagi08","avatar":"https://static.tigerbbs.com/04a6ca80d31900bae8ec95b23446e79d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582026494482473"},"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/126271626","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5003008,"gmtCreate":1624577618255,"gmtModify":1663229951045,"authorId":3558581504257803,"author":{"id":3558581504257803,"authorId":3558581504257803,"name":"Kelvinyoon26","avatar":"https://static.tigerbbs.com/17c18f026fcaa77f437cb20f39e1b4ef","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126271626,"type":1,"supId":5002964,"prevId":0,"content":"?","text":"?","html":"?"},{"id":5002964,"gmtCreate":1624577494734,"gmtModify":1663229948444,"authorId":3581764693783243,"author":{"id":3581764693783243,"authorId":3581764693783243,"name":"Junren92","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126271626,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"},{"id":5004428,"gmtCreate":1624581138329,"gmtModify":1635247570161,"authorId":3581848609787274,"author":{"id":3581848609787274,"authorId":3581848609787274,"name":"IZLIN","avatar":"https://static.tigerbbs.com/f2241963762942310c858a3aae49c0d1","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126271626,"type":1,"supId":0,"prevId":0,"content":"[Thinking]","text":"[Thinking]","html":"[Thinking]"}],"langContent":"EN"},{"id":126244226,"gmtCreate":1624577211565,"gmtModify":1703840592364,"author":{"id":"3561940699575283","authorId":"3561940699575283","authorIdStr":"3561940699575283","name":"HenryGoei","avatar":"https://static.tigerbbs.com/a1049cc393c97ed4e179dbc46d637883","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3561940699575283"},"htmlText":"I will go buy","listText":"I will go buy","text":"I will go buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126244226","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126245791,"gmtCreate":1624577187313,"gmtModify":1703840591232,"author":{"id":"3580932551134778","authorId":"3580932551134778","authorIdStr":"3580932551134778","name":"SteveGoh","avatar":"https://community-static.tradeup.com/news/11095a7766734a010cae2953dbc20e3e","vip":1,"crmLevel":1,"crmLevelSwitch":1,"idStr":"3580932551134778"},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/126245791","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5006057,"gmtCreate":1624585658548,"gmtModify":1663229966136,"authorId":3581556843549192,"author":{"id":3581556843549192,"authorId":3581556843549192,"name":"SerenityMie","avatar":"https://static.tigerbbs.com/7beaf0f50fa9c54132bac0579576b755","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126245791,"type":1,"supId":5002877,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"},{"id":5002877,"gmtCreate":1624577244331,"gmtModify":1663229947947,"authorId":3579207760920564,"author":{"id":3579207760920564,"authorId":3579207760920564,"name":"Thengz","avatar":"https://static.tigerbbs.com/eb87a2ba614bf594d49c299bab92466e","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.61%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":9,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126245791,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":126242013,"gmtCreate":1624577128232,"gmtModify":1703840587972,"author":{"id":"3580034838470052","authorId":"3580034838470052","authorIdStr":"3580034838470052","name":"Newcomer007","avatar":"https://static.tigerbbs.com/72ffc8b15ab7b4af0760f48a0e342ba1","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3580034838470052"},"htmlText":"Nice.","listText":"Nice.","text":"Nice.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126242013","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126246786,"gmtCreate":1624577127445,"gmtModify":1703840587809,"author":{"id":"3576274545052910","authorId":"3576274545052910","authorIdStr":"3576274545052910","name":"Kevin92","avatar":"https://static.tigerbbs.com/c5ff4addbbdb8d9d15fec29f9709b0c3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576274545052910"},"htmlText":"lke and comment","listText":"lke and comment","text":"lke and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/126246786","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5002858,"gmtCreate":1624577175518,"gmtModify":1663229947948,"authorId":3580932551134778,"author":{"id":3580932551134778,"authorId":3580932551134778,"name":"SteveGoh","avatar":"https://community-static.tradeup.com/news/11095a7766734a010cae2953dbc20e3e","vip":1,"crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126246786,"type":1,"supId":0,"prevId":0,"content":"like and back please","text":"like and back please","html":"like and back please"}],"langContent":"EN"},{"id":126241791,"gmtCreate":1624577077113,"gmtModify":1703840585372,"author":{"id":"3581984006176179","authorId":"3581984006176179","authorIdStr":"3581984006176179","name":"kukumolu","avatar":"https://static.tigerbbs.com/968c9b6dacd85f184faef66f2db6a7a7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581984006176179"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/126241791","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5002840,"gmtCreate":1624577121742,"gmtModify":1663229949844,"authorId":3576274545052910,"author":{"id":3576274545052910,"authorId":3576274545052910,"name":"Kevin92","avatar":"https://static.tigerbbs.com/c5ff4addbbdb8d9d15fec29f9709b0c3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126241791,"type":1,"supId":0,"prevId":0,"content":"lke and comment","text":"lke and comment","html":"lke and comment"},{"id":5002862,"gmtCreate":1624577186366,"gmtModify":1663229947841,"authorId":3565748813055105,"author":{"id":3565748813055105,"authorId":3565748813055105,"name":"TradeInWind","avatar":"https://static.tigerbbs.com/0bde265e1fc6edfc01f2900838c12358","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":126241791,"type":1,"supId":5002840,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":126257552,"gmtCreate":1624576941076,"gmtModify":1703840578691,"author":{"id":"3581938240380182","authorId":"3581938240380182","authorIdStr":"3581938240380182","name":"Legend_传奇","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581938240380182"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126257552","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126254909,"gmtCreate":1624576890801,"gmtModify":1703840578529,"author":{"id":"3566244878628904","authorId":"3566244878628904","authorIdStr":"3566244878628904","name":"Wallstrtbets","avatar":"https://static.tigerbbs.com/6c38bbee1121ea92508ad9508fa15c5e","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3566244878628904"},"htmlText":"Arked.","listText":"Arked.","text":"Arked.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126254909","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126255215,"gmtCreate":1624576880437,"gmtModify":1703840578364,"author":{"id":"3577791630498857","authorId":"3577791630498857","authorIdStr":"3577791630498857","name":"wooooow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577791630498857"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126255215","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126255100,"gmtCreate":1624576872700,"gmtModify":1703840575231,"author":{"id":"3569807126010989","authorId":"3569807126010989","authorIdStr":"3569807126010989","name":"happymoney","avatar":"https://static.tigerbbs.com/c7b835f693b89bd9b980cc013a40c669","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3569807126010989"},"htmlText":"Cathie buy, i buy","listText":"Cathie buy, i buy","text":"Cathie buy, i buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126255100","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126251636,"gmtCreate":1624576774025,"gmtModify":1703840570019,"author":{"id":"3567411499210880","authorId":"3567411499210880","authorIdStr":"3567411499210880","name":"Nebhol","avatar":"https://static.tigerbbs.com/b0bfc2a45b91e41a283614268857b3a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3567411499210880"},"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126251636","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126224994,"gmtCreate":1624576599418,"gmtModify":1703840562203,"author":{"id":"3554864697888884","authorId":"3554864697888884","authorIdStr":"3554864697888884","name":"Blim","avatar":"https://static.tigerbbs.com/f92a854ac5b40d9557fa9c7a8ddaa54f","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3554864697888884"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126224994","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":126228336,"gmtCreate":1624576429125,"gmtModify":1703840556197,"author":{"id":"3563311381284357","authorId":"3563311381284357","authorIdStr":"3563311381284357","name":"MaxWin","avatar":"https://static.tigerbbs.com/a7681dcc0f2b046cc74cca2972ae6fc3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3563311381284357"},"htmlText":"<a href=\"https://laohu8.com/U/3576152954331303\">@kellyWin</a><a href=\"https://laohu8.com/U/3586854163859420\">@chokim</a><a href=\"https://laohu8.com/U/4087214947564360\">@NgeChanWin</a>hhuat","listText":"<a href=\"https://laohu8.com/U/3576152954331303\">@kellyWin</a><a href=\"https://laohu8.com/U/3586854163859420\">@chokim</a><a href=\"https://laohu8.com/U/4087214947564360\">@NgeChanWin</a>hhuat","text":"@kellyWin@chokim@NgeChanWinhhuat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126228336","repostId":2145704596,"repostType":4,"repost":{"id":"2145704596","pubTimestamp":1624533000,"share":"https://ttm.financial/m/news/2145704596?lang=&edition=fundamental","pubTime":"2021-06-24 19:10","market":"us","language":"en","title":"3 Stocks Cathie Wood Is Buying That Should Be on Your List Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2145704596","media":"Motley Fool","summary":"These beaten-down stocks could still be big winners over the long run.","content":"<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).</p>\n<p>Wood deservedly stands out as <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.</p>\n<p><img src=\"https://static.tigerbbs.com/9785217426a2fa18e6698fdddd817769\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Etsy</h3>\n<p><b>Etsy</b> (NASDAQ:ETSY) isn't among the largest holdings in Wood's <b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b>. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.</p>\n<p>After a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.</p>\n<p>The COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.</p>\n<p>More importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly <a href=\"https://laohu8.com/S/AONE.U\">one</a> week after the acquisition was announced.</p>\n<h3>Unity Software</h3>\n<p><b>Unity Software</b> (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b> and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.</p>\n<p>Like Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.</p>\n<p>Unity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.</p>\n<p>The company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.</p>\n<h3>Vertex Pharmaceuticals</h3>\n<p>Wood remains a big fan of biotech stocks, with&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the <b>ARK Genomic Revolution ETF</b>.</p>\n<p>Vertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"</p>\n<p>Although Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.</p>\n<p>In the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with <b>CRISPR Therapeutics</b>, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Cathie Wood Is Buying That Should Be on Your List Too</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Cathie Wood Is Buying That Should Be on Your List Too\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 19:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"U":"Unity Software Inc.","ETSY":"Etsy, Inc.","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/06/24/3-stocks-cathie-wood-is-buying-that-should-be-on-y/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145704596","content_text":"Sure, Cathie Wood's ARK Invest exchange-traded funds (ETFs) haven't been big winners so far this year. However, it's a much different story over a longer period. Three of the ARK ETFs rank in the top 10 best performers (and the only ETFs with greater returns are all leveraged).\nWood deservedly stands out as one of the most successful stock pickers around. The good news is that small investors can profit from her ideas just as she can. Here are three especially promising stocks that Cathie Wood is buying that should be on your list, too.\n\nImage source: Getty Images.\nEtsy\nEtsy (NASDAQ:ETSY) isn't among the largest holdings in Wood's ARK Next Generation Internet ETF. However, Wood clearly likes the e-commerce stock and scooped up more shares earlier this month.\nAfter a fantastic performance in 2020, Etsy's shares are around 25% below their highs from earlier this year. Some investors are less bullish about the stock because Etsy expects its growth rate to decelerate after the pandemic-fueled surge. I suspect that Wood sees a huge long-term opportunity for the company that puts any temporary growth slowdown in perspective.\nThe COVID-19 pandemic made Etsy more visible than ever before. Not only does the company have more users, but an increasing number of them have also become repeat buyers. Even with growth rates slowing, Etsy's actual growth remains impressive.\nMore importantly, the company has only scratched the surface of the market potential for the handcrafted products that have made it a go-to site for consumers. Etsy is also expanding beyond its niche by acquiring London-based online clothing reseller Depop. This deal appears to be a smart move for Etsy. Wood seemingly agrees since she bought more shares roughly one week after the acquisition was announced.\nUnity Software\nUnity Software (NYSE:U) clearly ranks as one of Wood's favorite stocks. It's the eighth-largest holding in the ARK Innovation ETF and No. 10 holding in the ARK Next Generation Internet ETF. And Wood bought more shares of the gaming platform company for both ETFs in June.\nLike Etsy, Unity is well off its peak from earlier this year. Also like Etsy, Unity expects its growth to slow somewhat after a sizzling performance during 2020. Wood, however, knows that focusing on the long term is the way to make money investing.\nUnity's executives believe the company's addressable market totals close to $29 billion. Its biggest opportunity is in online gaming. Over half of the top mobile games, PC games, and console games were developed using Unity's platform.\nThe company also sees plenty of room for growth outside of gaming that could expand its addressable market significantly. Developers are using Unity's platform to design automobiles and buildings, simulate autonomous driving, use augmented reality in employee training, and more. Unity is the kind of stock that just might double your money over the next few years -- and Wood knows it.\nVertex Pharmaceuticals\nWood remains a big fan of biotech stocks, with Vertex Pharmaceuticals (NASDAQ:VRTX) as one of her top picks. It's the sixth-largest position in the ARK Genomic Revolution ETF.\nVertex announced a setback earlier this month with alpha-1 antitrypsin deficiency (AATD) candidate VX-864. Although the experimental drug met the primary endpoint of a phase 2 study, the company opted not to advance it into late-stage testing because it wasn't likely to achieve a \"substantial clinical benefit.\"\nAlthough Vertex's shares tanked on the news, Wood saw a buying opportunity. Vertex enjoys a monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). As a result, it's amassed a growing cash stockpile that will likely be put to use in acquiring and/or licensing new pipeline programs.\nIn the meantime, Vertex has several promising candidates outside of CF. CTX001, a gene-editing therapy being developed with CRISPR Therapeutics, could effectively cure rare blood disorders beta-thalassemia and sickle cell disease. Vertex thinks that VX-147 could be a winner in treating kidney diseases in individuals with APOL1 gene variants. It's also evaluating a gene therapy in early-stage clinical testing targeting type 1 diabetes.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":597,"commentSize":173,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}